The treatment of imported malaria in children: An update

Archives of Disease in Childhood: Education and Practice Edition

Volumn 98, Issue 1, 2013, Pages 7-15

  Kiang, Karen M ^a,b   Bryant, Penelope A ^b,c   Shingadia, Delane ^d   Ladhani, Shamez ^e,f   Steer, Andrew C ^a,b   David, Burgner ^b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c Monash Children's Southern Health   (Australia)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMATEM; AMODIAQUINE; ARSUCAM; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; COARSUCAM; COARTEM D; COTECXIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; FAVERID; LONART; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; PYRONARIDINE; QUININE; UNCLASSIFIED DRUG; WINTHROP;

ANTIMICROBIAL THERAPY; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; GAMETOCYTE; HUMAN; LOADING DRUG DOSE; MALARIA; MALARIA FALCIPARUM; NONHUMAN; OUTPATIENT CARE; OVERALL SURVIVAL; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG THERAPY, COMBINATION; ENDEMIC DISEASES; GREAT BRITAIN; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRACTICE GUIDELINES AS TOPIC; PRIMAQUINE; QUININE;

EID: 84873097701     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301530     Document Type: Review

References (33)

1. Barber BE, William T, Jikal M, et al. Plasmodium knowlesimalaria in children. Emerg Infect Dis 2011;17:814-20.
2. Anstey NM, Russell B, Yeo TW, et al. The pathophysiology of vivax malaria. Trends Parasitol 2009;25:220-7.
3. Lacerda MV, Mourao MP, Alexandre MA, et al. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J 2012;11:12.
4. Price RN, Douglas NM, Anstey NM, et al. Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis 2011;24:578-85.
5. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007;77(6 Suppl):79-87.
6. William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011;17:1248-55.
7. World Health Organization. World malaria report 2011. Geneva: World Health Organization, December 2011.
8. Mali S, Tan KR, Arguin PM. Malaria surveillance - United States, 2009. MMWR Surveill Summ 2011;60:1-15.
9. Health Protection Services. Migrant health: infectious diseases in non-UK born populations in the United Kingdom. An update to the baseline report - 2011. London: Health Protection Agency, 2011.
10. Shingadia D, Ladhani S. UK treatment of malaria. Arch Dis Child Educ Pract Ed 2011;96:87-90.
11. National Notifiable Diseases Surveillance System (database on the Internet). http://www9.health.gov.au/cda/Source/CDA-index.cfm (accessed 30 Nov 2011).
12. Agnandji ST, Kurth F, Belard S, et al. Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa. Wien Klin Wochenschr 2011;123(1 Suppl):7-9.
13. World Health Organization. Guidelines for the treatment of malaria, 2nd edn. Geneva: World Health Organization, 2010.
14. Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004;48:4234-9.
15. Morris CA, Duparc S, Borghini-Fuhrer I, et al. Reviewof the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 2011;10:263.
16. Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-25.
17. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-57.
18. Sinclair D, Donegan S, Isba R, et al. Artesunate versus quininefor treating severe malaria. Cochrane Database Syst Rev 2012;(6):CD005967.
19. Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States. Atlanta: Center for Disease Control and Prevention. http://www.cdc.gov/malaria/diagnosis-treatment/artesunate.html (accessed 11 Nov 2011).
20. eTG complete. Melbourne: Therapeutic Guidelines Limited; 2010 (updated March 2010). (accessed 12 Oct 2011).
21. Public Health Agency of Canada. Canadian recommendations for the prevention and treatment of malaria among international travellers - 2009. Can Commun Dis Rep 2009;35(Suppl 1):1-82.
22. Lalloo DG, Shingadia D, Pasvol G, et al. UK malaria treatment guidelines. J Infect 2007;54:111-21.
23. Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000;44:1680-5.
24. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009;(3):CD007483.
25. Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405-16.
26. Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis 2011;5:e1325.
27. Sinclair D, Gogtay N, Brand F, et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 2011; (7):CD008492.
28. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67.
29. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379:1960-6.
30. Myint HY, Berman J, Walker L, et al. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Am J Trop Med Hyg 2011;85:1010-14.
31. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J 2008;7(Suppl 1):S8.
32. Melzer M, Lacey S, Rait G. The case for outpatient treatment of Plasmodium falciparum malaria in a selected UK immigrant population. J Infect 2009;59:259-63.
33. Cherian S, Burgner D. Selective ambulatory management of Plasmodium falciparum malaria in paediatric refugees. Arch Dis Child 2007;92:983-6.